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ADJUVANT  POLYARTHRITIS 
V. Induction by Noacetylmuramyl-L-alanyl-D-isoglutamine, 
the Smallest  Peptide Subunit of Bacterial Peptidoglycan* 
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Adjuvant arthritis in the rat can be induced by a single injection of a dispersion of 
certain dried, heat-killed microorganisms such as mycobacteria, corynebacteria, strep- 
tococci, or their cell wall components such as peptidogiycan and certain peptidogtycan 
subunits in a suitable oily vehicle (1, 2). The pathogenesis of adjuvant arthritis is not 
yet clearly understood. There is an impressive body of evidence indicating that  the 
disease arises from an aberrant immune response (3-5) primarily involving the cell- 
mediated (delayed) hypersensitivity (6), although the humoral immune response may 
also play a  role at  an  early stage  of the disease development  (7).  The  identity or 
nature of the etiologic immunogen responsible for the disease is not known; compo- 
nents of bacterial cell wall and host tissue proteins are two likely possibilities (8, 9), 
Supporting  the  view  that  adjuvant  disease  in  the  rat  may  be  an  autoimmune 
phenomenon resulting in the development of autoantibodies and/or specific sensitized 
lymphocytes acting against  the animal's own tissues  (3, 6, 8)  were the observations 
that polyarthritis in the rat, similar to the classic adjuvant arthritis, can be induced 
by  oily preparations  of type  II  collagen,  and  by an  apparently  nonimmunogenic 
synthetic adjuvant completely unrelated to materials of bacterial cell wall origin (10). 
We now report that N-acetylmuramyl-e-alanyl-v-isoglutamine (MDP), the smallest 
peptide  subunit  of bacterial  peptidoglycan  (11),  having adjuvant  activity but  not 
immunogenicity, induced a  polyarthritis in the rat when injected in the form of an 
oily  emulsion.  On  the  other  hand,  its  diastereomer,  N-acetylmuramyl-e-alanyl-e- 
isoglutamine (12), which has neither adjuvant activity nor immunogenicity, failed to 
induce the disease. 
Materials and Methods 
Animals and Materials. Male Lewis rats weighing  235-250  g were purchased from Microbio- 
logical  Associates, Walkersville,  Md.;  EL-4 tumor cells were obtained as a  girl  from Dr. J. 
Wunderlich (National Institutes of Health, Bethesda, Md.) and were maintained by passage in 
syngeneic C57BL/6 mice (The Jackson Laboratory, Bar Harbor, Maine). 51Cr (200-300 mCi/ 
mg sp ac)  was  purchased from Abbott Diagnostics,  North Chicago, Ill.  Freund's complete 
adjuvant  (FCA) was  prepared by grinding powdered Mycobacterium butyricum (10 rag;  Difeo 
Laboratories, Detroit, Mich.) with mineral oil (1.01 ml; Primol 355, Hampden Color Chemical 
Company). N-acetylmuramyl-L-alanyI-L-isoglutamine  was purchased from Calbiochem-Behr- 
ing Corp., American Hoechst Corp., San Diego, Calif. 
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Adjuvant Arthritis.  Adjuvant arthritis was produced by a single intradermal  injection of a 
given preparation of adjuvant into the tail or one of the hind footpads of male Lewis inbred 
rats. The volume of the uninjected hind footpad was measured by the method of Winter et al. 
(13) on days 0 and  16, with respect to the injection of adjuvant, unless  otherwise noted. 
SlCr-labeling of EL-4  Cells.  Both the humoral and cellular assays of immune response are 
based  upon  the  lysis of 51Cr-labeled  EL-4 cells.  Labeling was carried  out  according to the 
method of Canty and Wunderlich (14). 
Humoral and cell-mediated Immunity to EL-4 Cells.  Humoral and cell-mediated  immunity to 
EL-4 cells were measured according to a previously reported procedure (15). 
Results 
Adjuvant Effect of MDP.  Groups of seven rats were injected  intraperitoneally  with 
either saline  (0.5 ml), FCA (0.1  ml), a  suspension of 5 ×  107 EL-4 cells in saline  (0.5 
ml),  a  suspension  of 5  ×  10  7 EL-4 cells  (0.5  ml)  plus  Freund's  incomplete  adjuvant 
(FIA;  0.1  ml),  a  suspension  of 5  ×  10 v EL-4  cells  (0.5  ml)  plus  FCA  (0.1  ml),  a 
suspension of 5 ×  107 EL-4 cells (0.5 ml) plus emulsion of MDP in FIA (0.1  ml), or a 
suspension of 5 ×  107 EL-4 cells (0.5 ml) plus an emulsion of the MDP isomer in FIA 
(0.1  ml).  The  animals  were  killed  16  d  after  sensitization.  The  spleen  was  then 
removed and  a  blood sample  collected.  The complement-independent  lysis of 51Cr- 
labeled  EL-4 cells by the spleen lymphocytes was determined and used as a  measure 
of cell-mediated immune response to EL-4 cells. The antibody titer of the serum was 
determined  by using  51Cr-labeled  EL-4 cells.  Results  are  shown  in  Fig.  1.  Animals 
that  received  an  intraperitoneal  injection  of a  suspension  of EL-4  cells  in  saline 
developed both humoral and cell-mediated immune responses to EL-4 cells. Both the 
humoral  and  the cell-mediated  immune  responses were augmented  in animals  that 
received  an  injection  of EL-4 suspended  in  FCA or in an emulsion  of MDP  in  FIA 
(P <  0.01).  No enhancement  was observed  in  animals  that  received  an  injection  of 
EL-4 cells suspended  in an emulsion  of N-acetylmuramyl-L-alanyl-h-isoglutamine in 
FIA (P >  0.1). 
Development of Arthritis after the Injection of FCA, MDP in FIA, or N-acetyt-L-alanyt-L- 
isoglutamine in FIA.  A subplantar injection of either FCA (0.1  ml), emulsion of MDP 
in FIA (5.0 mg/ml, 0.1  ml), emulsion of N-acetylmuramyl-h-alanyl-L-isoglutamine in 
FIA  (5.0  mg/ml,  0.1  ml),  or saline  (0.1  ml)  was  administered  to  Lewis  rats  (seven 
animals  per group), and the volume of the uninjected  hindfootpads of each rat  was 
measured  at  regular  intervals  for  16  d.  The  results  are  plotted  in  Fig.  2.  The 
development  of arthritis  in  animals  given  MDP  followed  the  same  time  course  as 
animals injected with FCA. The disease had become well established  by day 16. 
Dermal Hypersensitivity Reactions in  Rats  with  MDP-induced  Polyarthritis.  Groups  of 
seven rats were given a  subplantar  injection  (0.1  ml)  of saline,  an emulsion of MDP 
in FIA (5.0 mg/ml, 0.1 ml), an emulsion of MDP in FCA (5.0 mg/ml), or an emulsion 
of N-acetyl-L-alanyl-L-isoglutamine in FIA (5.0 mg/ml, 0.1  ml). On the  16th d  after 
injection, all animals were given intradermal  injections of 0.1 ml of saline solutions of 
MDP  at  concentrations  of 6.25,  12.5,  25,  and  50  ~g/0.1  ml,  and  solutions  of N- 
acetylmuramyl-L-alanyl-L-isoglutamine at concentrations of 6.25,  12.5, 25, and 50/Lg/ 
0.1  ml. Observations were made at 4, 6, 24, and 48 h  after intradermal  injection.  No 
significant inflammation was observed at any injection site throughout the observation 
period. CHANG  ET  AL.  BRIEF  DEFINITIVE  REPORT  1023 
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The development of the humoral and the cell-mediated immune response to EL-4 cells in 
Lewis rats injected intraperitoneally with saline, FCA, or a suspension of EL-4 cells in:  1) saline; 2) 
FIA; 3) FCA; 4) an emulsion of MDP in FIA; and 4)  an emulsion of the isomer of MDP in FlA. 
The bars represent stimdard deviations. Antibody titers shown are means of four determinations 
with pooled sera. *Significantly different from the control values (P <  0.01). 
Discussion 
Adjuvant arthritis in the rat, as well as rheumatoid arthritis in humans, is believed 
to  arise  from  an  aberrant  immune  response  to  antigen(s)  whose  identity  remains 
elusive. The disease may be (a)  the result of a  delayed hypersensitivity response to 
bacilli or their constituents, such as peptidoglycans (2), which resist degradation by 
mammalian  lysosomal enzymes (17)  and may remain in macrophages to serve as a 
persistent source of immunogen; or (b) an autoimmune phenomenon brought about 
by the injection of adjuvant and resulting in the development of autoantibodies and/ 
or specific sensitized lymphocytes acting against the animal's own tissues (3, 6, 8). 
In an effort to identify the substances in the bacterial cell wall responsible for the 
induction of adjuvant disease, we and others have, during the past decade, isolated 
and identified many chemical moieties in the bacterial cell wall and tested for their 
ability to induce arthritis when mixed with an oil vehicle. Bacterial cell wall can be 1024  CHANG  ET  AL. 
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FIG- 2.  Kinetic study on the development of arthritis after a  single subplantar injection of saline 
(A), FCA (O), an emulsion of MDP in FIA (O), or an emulsion of the isomer of MDP, FIA ([]). 
replaced by wax  D,  a  chloroform-soluble fraction of cell wall  (18), and  by water- 
soluble cell wall fractions (2, 19). Both wax D and the water-soluble fractions contain 
a  peptidoglycan  moiety  that  was  found  to  be  arthritogenic.  Specific  enzymatic 
degradation  of cell-wall-derived peptidoglycan produced a  group of peptidoglycan 
subunits  (20). Two of the peptidoglycan subunits,  an oligosaccharide-hexapeptide  1 
and  a  disaccharide-hexapeptide  polymer  2 were  found  to  be capable  of producing 
adjuvant  arthritis.  An oligosaccharide-hexapeptide monomer was  nonarthritogenic. 
Whether these active materials induce adjuvant arthritis by providing the necessary 
etiologic antigen (immunogenici'ty) or by stimulating the immune response to certain 
intrinsic antigen(s)  within the host  (adjuvanticity) has not been clearly established. 
Certain  peptidoglycan  subunits,  such  as  disaccharide-hexapeptide, shown  to have 
adjuvant activity in the guinea pig, were found to be incapable of inducing adjuvant 
arthritis in the rat (2, 20). This apparent lack of correlation may be due to a difference 
in structural requirement between adjuvanticity and arthritogenicity. Alternatively, 
it may be due to a species difference between the guinea pig and the rat in structural 
requirements for adjuvanticity. The adjuvant activity of these materials in the rat has 
not  been  determined.  MDP  has  been  reported to  be  arthritogenic by Nagao  and 
] (N-acetylglucosaminyl-N-acetylmuramyl)a  ior41-N-(L-alanyl-D-isoglutaminyl-N-(Glycyl-glycine)-L-lysyl- 
D-alanine. 
2 (N-acetylgluc•saminy•-N-acetylmuramy••N-(L•alanany•-•-is•g•utaminy•-N-(glycy•-glycine)•L-•ysy•-D• 
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Tanaka (21)  and nonarthritogenic by others (2,  12). These differences could perhaps 
be related to some genetic or environmental (viral) factors. 
There is some suggestive evidence that supports the view that  the immunogen(s) 
responsible for the development of adjuvant arthritis is intrinsic, e.g., a constituent of 
host tissue, or a viral host protein complex. First, an oily preparation of an apparently 
nonimmunogenic  synthetic  compound,  N,N-dioctadecyl-N',N'-bis(2-hydroxyethyl)- 
propane-diamine, completely unrelated to bacterial cell wall materials, was found to 
be capable of inducing a polyarthritis in rats that was almost indistinguishable from 
classic adjuvant arthritis induced by FCA both in morphology and in the time course 
of disease  development  (10).  Second,  Trentham  et  al.  (22)  showed  that  a  single 
injection of an oil emulsion of native type II collagen induced a  chronic arthritis in 
Wistar rats that was similar to the classic adjuvant arthritis and appeared concurrently 
with the development of hypersensitivity to type II collagen. Third, there is circum- 
stantial evidence that the immunogen(s) responsible for the development of adjuvant 
arthritis might be a latent virus or virus-host-protein complex (10, 23). For example, 
administration of interferon-inducing substances, interferon-containing plasma from 
Sindbis virus-infected rats, or interferon prepared in vitro from cultures of rat embryo 
fibroblasts (23), was reported to suppress the development of adjuvant arthritis. 
The present finding that an apparently nonimmunogenic, bacterial peptidoglycan- 
derived small peptide was capable of inducing adjuvant arthritis lends further support 
to the view that intrinsic immunogen(s) play a role in the development of this disease. 
The development of autoimmunity to such immunogen(s) requires adjuvant stimu- 
lation because N-acetylmuramyl-L-alanyl-r-isoglutamine, which does not possess ad- 
juvant activity, failed to produce the disease. 
Torisu et al.  (24)  reported that  6% of the patients with cancer who had received 
bacille Calmette-Gu~rin immunotherapy developed arthritis  that  was considered a 
side  effect of bacterial  adjuvant.  The  present  results  and  the  previous  finding  of 
arthritogenicity of an alkyldiamine (10) suggest that the arthritogenesis as a side effect 
in some situations may not be limited to bacterial adjuvant. 
Summary 
N-acetylmuramyl-L-alanyl-D-isoglutamine (MDP), an apparently nonimmunogenic 
bacterial peptidoglycan-derived small peptide, was found to induce a polyarthritis in 
the rat similar to that induced by Freund's complete adjuvant when injected in the 
form of an oil emulsion. An oil emulsion of its isomer, N-acetylmuramyl-L-alanyl-L- 
isoglutamine, which unlike MDP has no immunostimulatory activity, failed to induce 
the disease. 
Received  for publication 15 December 1980. 
References 
1.  Pearson,  C.  M.  1956. Development of arthritis, periarthritis and periostitis  in rats given 
adjuvants. Proc. Soc. Exp.  Biol. Med. 91:95. 
2.  Kohashi, O.,  C.  M.  Pearson,  T. Shimono, and S.  Kotani.  1976. Preparation of various 
fractions from Mycobacterium smegmatis, their arthritogenicity and their preventive effect on 
adjuvant disease. Int. Arch. Allergy Appl.  lmmunol. 51:451. 
3.  Pearson,  C.  M., and F. D. Wood.  1964. Passive transfer of adjuvant arthritis by lymph 
node or spleen cells.J. Exp. Med.  120:547. 1026  CHANG ET AL.  BRIEF DEFINITIVE REPORT 
4.  Currey, H. L. S. 1970. Adjuvant arthritis in the rat. Effect of Mycobacteria or tuberculin. 
Ann. Rheum. Dis. 29:.3140. 
5.  Currey,  H.  L.  S.,  and  M.  Ziff.  1968. Suppression  of adjuvant  disease  in  the  rat  by 
heterologous antilymphocyte globulin.J. Exp. Med. 127:185. 
6.  Waksman, G. H., C.  M.  Pearson, and J.  T.  Sharp.  1960. Studies of arthritis and other 
lesions induced in rats by injection of Mycobacterial adjuvant. II. Evidence that the disease 
is a disseminated immunologic response to exogenous antigen. J. lmmunol. 85:403. 
7.  Mackenzie, A. R., C.  R.  Pick, P.  R.  Sibley, and  B.  P. White.  1978. Suppression of rat 
adjuvant disease by cyclophosphamide pretreatment: evidence for an antibody mediated 
component in the pathogenesis of the disease. Clin. Exp. Immunol. 32:85. 
8.  Newbould, B.  H.  1964.  Role of lymph nodes in adjuvant-induced arthritis in rats. Ann. 
Rheum. Dis. 23:392. 
9.  Chang, Y.-H., and C. M. Pearson. 1978. Pathogenesis of adjuvant arthritis in rats. Arthritis 
Rheum. 21:169. 
10.  Chang, Y.-H., C. M. Pearson, and C. Abe. 1980. Adjuvant polyarthritis. IV. Induction by 
a synthetic adjuvant: immunologic, histopathologic, and other studies. Arthritis Rheum. 23: 
62. 
11.  Ellouz, F., A. Adam, R. Ciorbaru, and E. Lederer.  1974. Minimal essential structure for 
adjuvant activity of bacterial peptidoglycan derivatives. Biochem. Biophys. Res. Comm. 59. 
1317. 
12.  Chedid,  L.,  F.  Audibert,  and  A.  G.  Johnson.  1978.  Biological  activities of muramyl 
dipeptide, a synthetic glycopeptide analogous to bacterial immunoregulatory agents. Prog. 
Allergy 25:63. 
13.  Winter, C. A., G. A. Risley, and G. W. Nuss.  1962. Carrageenan-induced edema in hind 
paw of the rat as an assay of antiinflammatory drugs. Proc. Soc. Exp. Biol. Med. 111:544. 
14.  Canty, T. G., and J. R. Wunderlich. 1970. Quantitative in vitro assay of cytotoxic cellular 
immunity.,]. Natl. Cancer  Inst. 45:761. 
15.  Chang, Y.-H.  1977. Adjuvant polyarthritis. I. Incorporation of quantitative measures of 
humoral and cellular immune response. J. Pharmacol. Exp.  Ther. 201:1. 
16.  Kabat,  E.  A.,  and  M.  M.  Mayer.  1961. Experimental  Immunochemistry,  Charles  C. 
Thomas, Publisher, Springfield, Ill. 136. 
17.  Adler, E., H. Heller, E. Weinger, A. Masover, S. Friedman, M. Lahau, N. NeWman, and I. 
Ginsberg. 1973. Degradation of X4C-labeled group A streptococci and icrococci in muscular 
lesions in the mouse. 1st. J. Med. Sci. 9:483. 
18.  ~¢ood, F. D., C. M. Pearson, and A. Tanaka. 1969. Capacity of mycobacterial Wax D and 
its subfractions to induce adjuvant arthritis in rats. Int. Arch. Allergy Appl. Immunol. 35:456. 
19.  Koga, T., C. M. Pearson, T. Marita, and S. Kotani. 1973. Polyarthritis induced in the rat 
with cell walls from several bacteria and two streptomyces species. Proc. Soc. Exp. Biol. Med. 
143:824. 
20.  Kohashi, O., C.  M.  Pearson, Y.  Watanabe,  S.  Kotani, and  T.  Koga.  1976.  Structural 
requirements for arthritogenicity of peptidoglyeans from Staphylococcus aureus and LactobaciL 
lus plantarium and analogous synthetic compounds. J. Immunol. 116:1635. 
21.  Nagao, S., and A. Tanaka.  1980. Muramyl dipeptide induced adjuvant arthritis. Infect. 
Immun. 28:624. 
22.  Trentham, D. E., A. S. Townes, and A. H. Kang.  1977. Autoimmunity Type II collagen: 
an experimental model of arthritis. J. Exp. Med. 146:856. 
23.  Chang, Y.-H., and W. Hoffman.  1977. Adjuvant polyarthritis. III. Evidence in support of 
viral etiology. Arthritis Rheum. 20.1507. 
24.  Torisu, M., T. Miyahara, N. Shinohara, K. Ohsato, and H.  Sonozaki. 1978. A  new side 
effect of BCG: immunotherapy-BCG-induced arthritis in man. Cancer Immunol. Immunother. 
5:77. 